<DOC>
	<DOCNO>NCT02015169</DOCNO>
	<brief_summary>We plan study investigate efficacy safety XELOX ( capecitabine oxaliplatin ) plus lapatinib treatment HER2-positive gastric cancer patient liver metastasis .</brief_summary>
	<brief_title>Phase II Study Neoadjuvant XELOX + Lapatinib HER2 ( + ) Gastric Cancer Patients With Liver Metastasis</brief_title>
	<detailed_description>Gastric cancer lead cause cancer death worldwide incidence 18.9/100,000 per year mortality rate 14.7/100,000 per year [ 1 ] common malignancy Korea [ 2 ] . Metastatic gastric cancer remain therapeutic challenge medical oncologist due poor prognosis . Several randomized phase III trial compare combination chemotherapy 5-fluorouracil ( 5-FU ) , doxorubicin , mitomycin ( FAM ) , 5-FU , doxorubicin , high-dose methotrexate ( FAMTX ) best supportive care demonstrate significantly prolong overall survival ( 8 - 10 month ) chemotherapy group compare best supportive care alone ( 3 - 5 month ) [ 3 , 4 ] . In quest novel therapeutic target gastric cancer , HER2 overexpression test report 6-35 % stomach gastroesophageal tumor [ 5 ] . Trastuzumab , humanize monoclonal antibody selectively target HER2 , show survival benefit patient HER2 ( + ) metastatic breast cancer [ 6-8 ] . The ToGA trial first randomize , prospective , multicenter , phase III trial study efficacy safety trastuzumab HER2 ( + ) GC [ 9 ] . Of 3,807 tumor sample screen Her2 status , 22.1 % Her2 positive 594 patient randomized receive chemotherapy alone chemotherapy + trastuzumab . The ToGA trial demonstrate significant survival benefit transtuzumab +chemotherapy compare chemotherapy alone arm : 13.5 vs. 11.1 month , respectively ( p=0.0048 ; HR 0.74 ; 95 % CI 0.60 , 0.91 ) . ORR 47.3 % trastuzumab + 5-FU/CDDP ( capecitabine/CDDP ) arm 34.5 % chemotherapy alone arm ( p=0.0017 ) . The ToGA trial first phase III trial demonstrate survival benefit molecularly target agent gastric cancer . Of note , 70 - 80 % patient HER2 overexpressing breast cancer respond trastuzumab due either primary acquire resistance . One important mechanism trastuzumab resistance accumulation truncate form HER2 receptor lack extracellular trastuzumab-binding domain ( Figure 2 ) . P95HER2 , amino terminally truncate carboxyl terminal fragment HER2 , frequently find HER2 ( + ) breast cancer cell line tumor specimen ( ~20 % ) [ 11 ] . Intriguingly , recent study show p95HER2 ( + ) breast cancer cell resistant trastuzumab remain sensitive antiproliferative effect tyrosine kinase inhibitor lapatinib , vitro vivo [ 11 ] . In addition , patient p95HER2 ( + ) breast cancer resistant trastuzumab significantly low response rate compare full-length HER2 ( + ) breast cancer ( 11.1 % vs 51.4 % , respectively ; P = 0.029 ) . We survey incidence p95HER2 expression fresh frozen tissue gastric cancer find &gt; 60 % HER2 ( 3+ ) GC demonstrate p95HER2 . Hence , role lapatinib may promise trastuzumab GC HER2 ( + ) patient truncation .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>1 . Histologically proven gastric cancer metastatic lesion ( ) ( ) unresectable locally advanced gastric cancer NOT resectable distant metastasis limit abdominal lymph node , liver : Patients liver metastasis : Number liver metastasis 2 5 maximal diameter 5 cm ( 2 = liver mets = 5 maximal diameter = 5cm ) No LN metastasis within group 3 bulky N2 metastasis Clinically distant metastasis ( lung metastasis , mediastinal LN metastasis , neck LN metastasis , bone metastasis , brain metastasis , peritoneal seed abdominal pelvis CT ; case suspicious peritoneal seed image without evidence ascites and/or peritoneal enhancement allow enter study base investigator ' decision ) chemonaïve ( adjuvant treatment allow last date treatment ≥ 6 month study entry date 2 . Age ≥ 18 3 . ECOG performance 0 1 4 . Adequate organ function ( AST ALT ≤2x upper limit normal , bilirubin ≤1.5 x upper limit normal , creatinine &lt; 1.5x upper limit normal , platelet &gt; 100,000/ul , absolute neutrophil count ≥ 1,500/ul ) 5 . At least one measurable lesion RECIST 1.1 criterion 6 . HER 2 ( + ) HercepTest ( IHC 3+ alone , IHC 2+ FISH amplification ) 7 . Written inform consent 1 . Prior therapy metastatic disease 2 . Pregnant lactate woman 3 . Uncontrolled medical illness include medically uncontrolled infection , uncontrolled hypertension , unstable angina , symptomatic congestive heart failure , myocardial infarction within 6 month 4 . Any comorbidities suitable general anesthesia surgical resection 5 . Distant metastasis liver abdominal lymph node ( As outline inclusion criterion , peritoneal seed abdominal pelvis CT ; case suspicious peritoneal seed image without evidence ascites and/or peritoneal enhancement allow enter study base investigator ' decision ) 6 . Known immediate delay hypersensitivity reaction lapatinib , capecitabine , oxaliplatin platinum compound , recipient . 8 ) Subjects DPD deficiency 9 ) Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) 10 ) Preexisting hand foot syndrome peripheral neuropathy grade 2 great 11 ) Subjects unsuitable resection general anesthesia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>lapatinib</keyword>
</DOC>